Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sigma-Aldrich names new vice president and corporate controller
Mr Kanan succeeds Karen Miller who was recently promoted to vice president of strategy and corporate development. Mr Kanan will report to Rakesh Sachdev, vice president and CFO.
Mr Kanan succeeds Karen Miller who was recently promoted to vice president of strategy and corporate development. Mr Kanan will report to Rakesh Sachdev, vice president and CFO.
In this role, Dr George will be responsible for managing external relationships with cancer agencies, organizations and specialists around the world. Most recently, Dr George held the position
Kai Pharmaceuticals, a drug discovery and development company, has initiated a third Phase IIa study of KAI-1678, an isozyme-selective, small peptide inhibitor of the epsilon protein kinase C
Ondine Biopharma, a biotechnology company, has entered into a non-binding letter of intent with JS Dental Technologies, a Toronto-based firm to purchase the company’s dental healthcare business. Subject
Arbor Vita, a biopharmaceutical company, has received 510(k) clearance from the FDA for its AVantage A/H5N1 flu test. According to Arbor Vita, AVantage flu test is a non-invasive
Eric Poma, CEO of Molecular Templates, said: “Cancer therapeutics is a crowded and competitive field. Molecular Templates’s platform technology is compelling because it allows us to rapidly screen
Maynard Howe, vice chairman and CEO of Stemedica, said: “Stemedica is executing a dual-path strategy in which the Stemedica USA facility will continue to manufacture current good manufacturing
According to SenoRx, this new version of the device incorporates a microminiaturization ultrasound technology that combines personal computing power and flexibility. The new ultrasound component is designed, developed
Dr Caggiano will continue to manage the preclinical and R&D departments, as well as oversee Acorda’s preclinical programs that aim to develop novel approaches to the treatment of
The series B financing included participation from all of Marinus’s existing investors, including Canaan Partners, Domain Associates, Sofinnova Ventures and Foundation Medical Partners. The funding will advance the